Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review

Hepatology Research

Volumn 44, Issue 10, 2014, Pages E11-E25

  Li, Changzai ^a   Zhang, Zhiming ^a   Zhang, Pan ^b   Liu, Jianyong ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b HEBEI UNITED UNIVERSITY   (China)

Author keywords

Des gamma carboxy prothrombin; Diagnostic; Hepatocellular carcinoma; Markers; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EARLY CANCER; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; LIVER CELL CARCINOMA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 84907864579     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12201     Document Type: Article

References (67)

1. Ferlay J, Shin HR, Bray F etal. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
3. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology 2009; 136: 1134-1144.
4. Lok AS, Sterling RK, Everhart JE etal. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
5. Forner A, Bruix J. Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol 2012; 13: 750-751.
6. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
7. Singal A, Volk ML, Waljee A etal. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
8. Liebman HA. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy)prothrombin. Cancer Res 1989; 49: 6493-6497.
9. King MA, Kew MC, Kuyl JM etal. A comparison between des-gamma-carboxy prothrombin and alpha-fetoprotein as markers of hepatocellular carcinoma in southern African blacks. J Gastroenterol Hepatol 1989; 4: 17-24.
10. Fujiyama S, Izuno K, Yamasaki K etal. Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves. Tumour Biol 1992; 13: 316-323.
11. Takikawa Y, Suzuki K, Yamazaki K etal. Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma. J Gastroenterol Hepatol 1992; 7: 1-6.
12. Grazi GL, Mazziotti A, Legnani C etal. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg 1995; 1: 249-255.
13. Nomura F, Ishijima M, Kuwa K etal. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 650-654.
14. Sassa T, Kumada T, Nakano S etal. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1999; 11: 1387-1392.
15. Ishii M, Gama H, Chida N etal. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000; 95: 1036-1040.
16. Cui R, Wang B, Ding H etal. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. Chin Med J (Engl) 2002; 115: 42-45.
17. Ikoma J, Kaito M, Ishihara T etal. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002; 49: 235-238.
18. Shimizu A, Shiraki K, Ito T etal. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis. Int J Mol Med 2002; 9: 245-250.
19. Marrero JA, Su GL, Wei W etal. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37: 1114-1121.
20. Wang CS, Lin CL, Lee HC etal. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005; 11: 6115-6119.
21. Kim J, Ki SS, Lee SD etal. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006; 101: 2051-2059.
22. Kim MJ, Bae KW, Seo PJ etal. Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma - using ROC curve. Korean J Hepatol 2006; 12: 404-411.
23. Nakamura S, Nouso K, Sakaguchi K etal. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101: 2038-2043.
24. Kim DY, Paik YH, Ahn SH etal. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007; 72: 52-57.
25. Volk ML, Hernandez JC, Su GL etal. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007; 3: 79-87.
26. Beale G, Chattopadhyay D, Gray J etal. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008; 8: 200.
27. Durazo FA, Blatt LM, Corey WG etal. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23: 1541-1548.
28. Lu F, Chen H, Gao M etal. Clinical value of des-(gamma)-carboxy prothrombin in the diagnosis of hepatocellular carcinoma. Chinese. J Clin Oncol 2009; 36: 361-364.
29. Marrero JA, Feng Z, Wang Y etal. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118.
30. Sterling RK, Jeffers L, Gordon F etal. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009; 7: 104-113.
31. Yamamoto K, Imamura H, Matsuyama Y etal. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009; 16: 2795-2804.
32. Morimoto M, Numata K, Nozaki A etal. Novel Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low alpha-fetoprotein concentrations. Int J Clin Oncol 2012; 17: 373-379.
33. Sterling RK, Wright EC, Morgan TR etal. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012; 107: 64-74.
34. Soroida Y, Ohkawa R, Nakagawa H etal. Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. J Hepatol 2012; 57: 330-336.
35. Mittal A, Gupta SP, Sathian B etal. Des-gamma-carboxyprothrombin for early identification and prognosis of hepatocellular carcinoma-a case control study from western Nepal. Asian Pac J Cancer Prev 2012; 13: 5773-5775.
36. Kanmura S, Uto H, Sato Y etal. The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol 2010; 45: 459-467.
37. Miura N, Maruyama S, Oyama K etal. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology 2007; 72: 45-51.
38. Choi JY, Jung SW, Kim HY etal. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World. J Gastroenterol 2013; 19: 339-346.
39. Ertle JM, Heider D, Wichert M etal. A combination of alpha-fetoprotein and des-gamma-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion 2013; 87: 121-131.
40. Mukozu T, Nagai H, Matsui D etal. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer Res 2013; 33: 1013-1022.
41. Tameda M, Shiraki K, Sugimoto K etal. Des-gamma-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma. Cancer Sci 2013; 104: 725-731.
42. Whiting PF, Rutjes AW, Westwood ME etal. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536.
43. Taketa K, Okada S, Win N etal. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama 2002; 56: 317-320.
44. Cui R, He J, Zhang F etal. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer 2003; 88: 1878-1882.
45. Gad A, Tanaka E, Matsumoto A etal. Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma. World. J Gastroenterol 2005; 11: 6607-6612.
46. Iizuka N, Sakaida I, Moribe T etal. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 2006; 26: 4713-4719.
47. Beneduce L, Pesce G, Gallotta A etal. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. Eur J Clin Invest 2008; 38: 571-577.
48. Zinkin NT, Grall F, Bhaskar K etal. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clinical. Cancer Res 2008; 14: 470-477.
49. Baek YH, Lee JH, Jang JS etal. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology 2009; 56: 763-767.
50. Yoon YJ, Han KH, Kim Y. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol 2009; 44: 861-866.
51. Ishida H, Matsuo S, Inoue Y. [Evaluation of diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for HCV related hepatocellular carcinoma developed after long-term follow up]. Rinsho Byori 2010; 58: 1065-1072.
52. Miura N, Osaki Y, Nagashima M etal. A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterol 2010; 10: 46.
53. Sharma B, Srinivasan R, Chawla YK etal. Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int 2010; 4: 569-576.
54. Yamamoto K, Imamura H, Matsuyama Y etal. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010; 45: 1272-1282.
55. Iizuka N, Oka M, Sakaida I etal. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. Clin Chim Acta 2011; 412: 152-158.
56. Kobashi H, Miyake Y, Ikeda F etal. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res 2011; 41: 405-416.
57. Morota K, Nakagawa M, Sekiya R etal. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, (alpha)-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med 2011; 49: 711-718.
58. Qu KZ, Zhang K, Li H etal. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45: 355-360.
59. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
60. Bertino G, Ardiri A, Malaguarnera M etal. Hepatocellualar carcinoma serum markers. Semin Oncol 2012; 39: 410-433.
61. Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol 2012; 39: 434-439.
62. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004; 127: S113-119.
63. Takeji S, Hirooka M, Koizumi Y etal. Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2013; 28: 671-677.
64. Sakamoto N. NX-PVKA assay, a conventional but refined prognostic biomarker for hepatocellular carcinoma. J Gastroenterol Hepatol 2013; 28: 755-756.
65. Tateishi R, Yoshida H, Matsuyama Y etal. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008; 2: 17-30.
66. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139: 46-50.
67. Gao P, Li M, Tian QB etal. Diagnostic performance of des-gamma-carboxy prothrombin (DCP) for hepatocellular carcinoma: a bivariate meta-analysis. Neoplasma 2012; 59: 150-159.